On August 7, Halozyme Therapeutics rose 5.38% in pre-market trading, trading at $90.9 per share, with turnover of $2,634.59.

The move was driven by the company's Q2 earnings release, which delivered a comprehensive beat across all key metrics. Q2 adjusted EPS came in at $2.28, surpassing the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, beating the consensus estimate of approximately $402 million by roughly 19%, up 47.7% year-over-year.

Simultaneously, the company significantly raised its full-year guidance, now expecting adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, up from prior guidance of $7.75 to $8.25 EPS on revenue of $1.71 billion to $1.81 billion. Both metrics substantially exceed FactSet consensus estimates of $7.94 EPS and $1.77 billion in revenue. The outperformance was primarily driven by continued strong royalty growth from its ENHANZE drug delivery technology platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)